Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain

• Published in: Future cardiology 2018-05, Vol.14 (3s), p.17-24
• Main Authors: Lobato, Sara Muñiz, Tarrazo, Carlos Tarrazo, Fernández, Elena González, Alcalá, Marlén Morán
• Format: Article
• Language: English
• Subjects: Age; Anticoagulants; atrial fibrillation; Cardiac arrhythmia; clinical practice; Clinical trials; discontinuation; Drug dosages; Embolisms; Family medical history; Patients; Primary care; rivaroxaban; ROCKET-AF; Stroke; Thromboembolism; XANTUS
• ISSN: 1479-6678; 1744-8298
• DOI: 10.2217/fca-2018-0022

To analyze the clinical profile and outcomes of patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital. Retrospective study of patients with nonvalvular atrial fibrillation that started treatment with rivaroxaban between July 2013 and May 2017 in a regional hospital. 189 patients (age 76.0 ± 9.4 years; CHA DS -VASc 4.1 ± 1.7; HAS-BLED 2.1 ± 0.9) were included. Rivaroxaban 20 mg was taken by 74.1% of patients. Among patients treated with rivaroxaban 20 and 15 mg, only 3.6 and 22.5%, respectively, received an inadequate dose. After 26.6 ± 11.6 months of treatment, annual discontinuation rate was 1%. Rates of stroke, major bleeding and intracranial hemorrhage were 0.45, 0.22 and 0.22 events/100 patient years, respectively. In our practice of regional hospital, rates of discontinuation, thromboembolic and bleeding outcomes are low.